FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003992884> ?p ?o ?g. }

• W2003992884 endingPage "1006" @default.
• W2003992884 startingPage "996" @default.
• W2003992884 abstract "In Brief Purpose: To evaluate the safety and preliminary efficacy of intravitreal ranibizumab for nonneovascular idiopathic macular telangiectasia Type 2. Methods: Single-center, open-label Phase II clinical trial enrolling five participants with bilateral nonneovascular idiopathic macular telangiectasia Type 2. Intravitreal ranibizumab (0.5 mg) was administered every 4 weeks in the study eye for 12 months with the contralateral eye observed. Outcome measures included changes in best-corrected visual acuity, area of late-phase leakage on fluorescein angiography, and retinal thickness on optical coherence tomography. Results: The study treatment was well tolerated and associated with few adverse events. Change in best-corrected visual acuity at 12 months was not significantly different between treated study eyes (0.0 ± 7.5 letters) and control fellow eyes (+2.2 ± 1.9 letters). However, decreases in the area of late-phase fluorescein angiography leakage (−33 ± 20% for study eyes, +1 ± 8% for fellow eyes) and in optical coherence tomography central subfield retinal thickness (−11.7 ± 7.0% for study eyes and −2.9 ± 3.5% for fellow eyes) were greater in study eyes compared with fellow eyes. Conclusion: Despite significant anatomical responses to treatment, functional improvement in visual acuity was not detected. Intravitreal ranibizumab administered monthly over a time course of 12 months is unlikely to provide a general and significant benefit to patients with nonneovascular idiopathic macular telangiectasia Type 2. The current Phase II clinical study used a paired, unilateral treated-eye design to assess sustained 12-month intravitreal ranibizumab on anatomical and functional progression in patients with idiopathic macular telangiectasia Type 2. The study results suggest that ranibizumab has no treatment impact on visual acuity, despite decreasing vascular leakage and retinal edema." @default.
• W2003992884 created "2016-06-24" @default.
• W2003992884 creator A5004857974 @default.
• W2003992884 creator A5016017455 @default.
• W2003992884 creator A5017028738 @default.
• W2003992884 creator A5066334310 @default.
• W2003992884 creator A5066443014 @default.
• W2003992884 creator A5090802305 @default.
• W2003992884 date "2012-05-01" @default.
• W2003992884 modified "2023-10-16" @default.
• W2003992884 title "TREATMENT OF NONNEOVASCULAR IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 WITH INTRAVITREAL RANIBIZUMAB" @default.
• W2003992884 cites W1599915172 @default.
• W2003992884 cites W1967274554 @default.
• W2003992884 cites W1976391708 @default.
• W2003992884 cites W1979047354 @default.
• W2003992884 cites W1981702879 @default.
• W2003992884 cites W1985972159 @default.
• W2003992884 cites W1987494452 @default.
• W2003992884 cites W1995443671 @default.
• W2003992884 cites W1999846890 @default.
• W2003992884 cites W2006202253 @default.
• W2003992884 cites W2008810667 @default.
• W2003992884 cites W2011837887 @default.
• W2003992884 cites W2013855450 @default.
• W2003992884 cites W2015343722 @default.
• W2003992884 cites W2036010344 @default.
• W2003992884 cites W2038749437 @default.
• W2003992884 cites W2038978104 @default.
• W2003992884 cites W2040362105 @default.
• W2003992884 cites W2052188656 @default.
• W2003992884 cites W2058546772 @default.
• W2003992884 cites W2059694718 @default.
• W2003992884 cites W2062406195 @default.
• W2003992884 cites W2070549270 @default.
• W2003992884 cites W2075198919 @default.
• W2003992884 cites W2104525395 @default.
• W2003992884 cites W2130134664 @default.
• W2003992884 cites W4294255520 @default.
• W2003992884 doi "https://doi.org/10.1097/iae.0b013e31824690a8" @default.
• W2003992884 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4696751" @default.
• W2003992884 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22266930" @default.
• W2003992884 hasPublicationYear "2012" @default.
• W2003992884 type Work @default.
• W2003992884 sameAs 2003992884 @default.
• W2003992884 citedByCount "34" @default.
• W2003992884 countsByYear W20039928842012 @default.
• W2003992884 countsByYear W20039928842013 @default.
• W2003992884 countsByYear W20039928842014 @default.
• W2003992884 countsByYear W20039928842015 @default.
• W2003992884 countsByYear W20039928842016 @default.
• W2003992884 countsByYear W20039928842017 @default.
• W2003992884 countsByYear W20039928842018 @default.
• W2003992884 countsByYear W20039928842019 @default.
• W2003992884 countsByYear W20039928842020 @default.
• W2003992884 countsByYear W20039928842022 @default.
• W2003992884 crossrefType "journal-article" @default.
• W2003992884 hasAuthorship W2003992884A5004857974 @default.
• W2003992884 hasAuthorship W2003992884A5016017455 @default.
• W2003992884 hasAuthorship W2003992884A5017028738 @default.
• W2003992884 hasAuthorship W2003992884A5066334310 @default.
• W2003992884 hasAuthorship W2003992884A5066443014 @default.
• W2003992884 hasAuthorship W2003992884A5090802305 @default.
• W2003992884 hasBestOaLocation W20039928842 @default.
• W2003992884 hasConcept C118487528 @default.
• W2003992884 hasConcept C141071460 @default.
• W2003992884 hasConcept C2776330896 @default.
• W2003992884 hasConcept C2776694085 @default.
• W2003992884 hasConcept C2777802072 @default.
• W2003992884 hasConcept C2778075232 @default.
• W2003992884 hasConcept C2778257484 @default.
• W2003992884 hasConcept C2778818243 @default.
• W2003992884 hasConcept C2780248432 @default.
• W2003992884 hasConcept C2780827179 @default.
• W2003992884 hasConcept C2781100027 @default.
• W2003992884 hasConcept C71924100 @default.
• W2003992884 hasConceptScore W2003992884C118487528 @default.
• W2003992884 hasConceptScore W2003992884C141071460 @default.
• W2003992884 hasConceptScore W2003992884C2776330896 @default.
• W2003992884 hasConceptScore W2003992884C2776694085 @default.
• W2003992884 hasConceptScore W2003992884C2777802072 @default.
• W2003992884 hasConceptScore W2003992884C2778075232 @default.
• W2003992884 hasConceptScore W2003992884C2778257484 @default.
• W2003992884 hasConceptScore W2003992884C2778818243 @default.
• W2003992884 hasConceptScore W2003992884C2780248432 @default.
• W2003992884 hasConceptScore W2003992884C2780827179 @default.
• W2003992884 hasConceptScore W2003992884C2781100027 @default.
• W2003992884 hasConceptScore W2003992884C71924100 @default.
• W2003992884 hasIssue "5" @default.
• W2003992884 hasLocation W20039928841 @default.
• W2003992884 hasLocation W20039928842 @default.
• W2003992884 hasLocation W20039928843 @default.
• W2003992884 hasLocation W20039928844 @default.
• W2003992884 hasOpenAccess W2003992884 @default.
• W2003992884 hasPrimaryLocation W20039928841 @default.
• W2003992884 hasRelatedWork W1751609384 @default.
• W2003992884 hasRelatedWork W1975075553 @default.
• W2003992884 hasRelatedWork W2003992884 @default.
• W2003992884 hasRelatedWork W2011837887 @default.

• next